查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088941

微生物組療法市場：2026-2032年全球市場預測（依產品、治療領域、劑型、原料、最終用途及通路分類）

Microbiome Therapeutics Market by Products, Therapeutic Area, Formulation, Source, End-use, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，微生物組療法市場將成長至 27.314 億美元，複合年成長率為 26.35%。

主要市場統計數據
基準年 2025 5.3119億美元
預計年份：2026年 6.6968億美元
預測年份 2032 27.314億美元
複合年成長率 (%) 26.35%

微生物組療法市場概覽

以微生物組為基礎的療法正從探索性科學階段邁向受監管的藥物階段，這主要得益於生物製藥產品、糞便微生物組衍生療法、特定微生物群落、後生元、基因改造菌株以及能夠調節宿主-微生物通路的小分子標靶藥物的出現。其中，在復發性困難梭狀桿菌感染疾病方面，已證實了最顯著的臨床療效。在此領域，美國FDA分別於2022年和2023年批准了首批糞便微生物組療法和口服微生物組療法，為基於微生物組的藥物研發樹立了監管先例。

微生物組療法前景的變革性變化

隨著監管環境的日益成熟、臨床選擇性的提高，以及從廣泛的糞便微生物移植轉向基於特定微生物群落和作用機制的候選藥物，微生物組療法的模式正在重新定義。研發人員優先考慮那些腸道菌群紊亂程度可測量、具有強力的生物學證據且存在明確未滿足需求的適應症，而不是僅僅追求具有普遍健康益處的微生物組調節療法。

人工智慧（AI）的累積影響

人工智慧 (AI) 透過輔助識別微生物特徵、預測患者反應以及確定治療聯合方案的優先順序，進一步提升了總體基因體學、代謝體學、轉錄組學、蛋白質組學和臨床資料集的價值。事實上，AI 正在加速菌株篩選、功能路徑映射、不利事件訊號傳導、臨床試驗參與者篩選以及發現最有可能獲益的患者的生物標記。

區域微生物組療法研究的關鍵見解

由於美國FDA的批准、成熟的臨床試驗基礎設施、學術微生物組研究中心以及與抗生素暴露和醫療相關感染疾病相關的複發性艱難梭菌性行為感染的高發生率，北美仍然是困難梭狀桿菌。美國在臨床試驗活動和早期商業化方面發揮核心作用，而加拿大則透過其醫院網路、公共衛生監測和轉化微生物組研究做出貢獻。

針對特定群體的全球市場合作夥伴關係的關鍵洞察

歐盟擁有舉足輕重的影響力，因為其監管協調、研究經費、藥物安全監測預期以及資料保護標準正在塑造微生物組療法的評估、生產和監測方式。七國集團（G7）擁有最先進的醫療基礎設施、報銷能力、專家和臨床試驗生態系統，在後期研發和真實世界數據（REW）的生成中發揮著至關重要的作用。

主要國家的趨勢推動市場擴張

美國在商業化過程中處於領先地位，這得益於FDA的先例、專業的臨床投資者、先進的定序能力以及大規模的感染疾病治療基礎設施。加拿大則透過大學醫院、微生物組研究計畫和綜合醫療數據系統來支持實證醫學的產生。同時，墨西哥和巴西在臨床應用方面不斷拓展，擁有豐富的胃腸病學專業知識，並在拉丁美洲地區佔據重要地位。在歐洲，英國、德國、法國、義大利和西班牙擁有先進的研究型醫院、強大的生命科學叢集以及監管生技藥品的經驗。然而，俄羅斯仍然受到地緣政治因素、資金籌措和監管複雜性的限制。

為行業領導者提供的實用建議

產業領導者應優先考慮那些具有已證實生物學機制、可實現終點且對保險公司具有明確意義的適應症。復發性困難梭狀桿菌感染疾病是一個成熟的切入點，但要實現持續的差異化，則需要進行患者分層、基於機制的生物標記，以及微生物組調節能夠帶來優於標準治療效果的證據。

調查方法

本執行摘要基於對公開監管記錄、同行評審的微生物組研究、臨床試驗註冊資訊、衛生機構指南、專利和政策趨勢以及宏觀經濟醫療保健指標的三角檢驗。主要參考領域包括美國食品藥物管理局 (FDA) 對基於微生物群療法的行動、世界衛生組織 (WHO) 和美國疾病管制與預防中心 (CDC) 對抗菌素抗藥性的優先事項、美國國立衛生研究院 (NIH) 支持的微生物組科學、歐洲監管指南以及區域生命科學政策趨勢。

結論

基於微生物組的療法正進入一個關鍵階段，除了科學創新之外，還需要臨床可重複性、嚴格的監管和可靠的生產。雖然已獲批准的基於微生物組的療法已在該領域展現出療效，但下一階段的發展取決於明確的作用機制、患者篩選、安全性監測以及可衡量的長期獲益。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 微生物組療法市場：依產品分類

  • 糞便微生物移植
  • 生物製藥
  • 基於微生物組的藥物
  • 微生物組生態系療法
  • 益生菌和益生元

第8章：微生物組療法市場：依治療領域分類

  • 自體免疫疾病
  • 癌症
  • 消化系統疾病
  • 感染疾病
  • 代謝性疾病
  • 神經病變

第9章：微生物組療法市場：依製劑類型分類

  • 口服
  • 外用

第10章：微生物組療法市場：依來源分類

  • 動物微生物組
  • 環境微生物組
  • 人類微生物組

第11章 微生物組療法市場：依最終用途分類

  • 學術和研究機構
  • 醫院和診所

第12章 微生物組療法市場：依通路分類

  • 離線
    • 醫院藥房
    • 零售藥房
  • 網路藥房

第13章 微生物組療法市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 微生物組療法市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 微生物組療法市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Alveolus Bio, Inc. by ResBiotic
  • AOBiome LLC
  • Assembly Biosciences, Inc.
  • Axial Therapeutics, Inc.
  • BioGaia AB
  • BiomeBank
  • EnteroBiotix Ltd
  • Enterome SA
  • Ferring BV
  • Intralytix, Inc.
  • Kanvas Biosciences
  • Locus Biosciences, Inc.
  • MaaT Pharma SA
  • Microba Life Sciences Limited
  • Microbiotica Ltd.
  • MRM Health NV
  • NuBiyota
  • Osel, Inc.
  • Pendulum Therapeutics
  • PharmaBiome AG
  • Pylum Biosciences
  • Seres Therapeutics, Inc.
  • Servatus Limited
  • Siolta Therapeutics
  • Theriva Biologics, Inc.
  • Vedanta Biosciences, Inc.
  • Viome Life Sciences, Inc. by BlueDot LLC
  • Xbiome Co. Ltd.
Product Code: MRR-ED54C46E807C

The Microbiome Therapeutics Market is projected to grow by USD 2,731.40 million at a CAGR of 26.35% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 531.19 million
Estimated Year [2026] USD 669.68 million
Forecast Year [2032] USD 2,731.40 million
CAGR (%) 26.35%

Microbiome Therapeutics Market Introduction

Microbiome therapeutics are moving from exploratory science into regulated medicine, led by live biotherapeutic products, fecal microbiota-based therapies, defined microbial consortia, postbiotics, engineered strains, and targeted small molecules that modulate host-microbe pathways. The strongest clinical validation is in recurrent Clostridioides difficile infection, where the U.S. FDA approved the first fecal microbiota-based and orally administered microbiota-based therapies in 2022 and 2023, establishing a regulatory precedent for microbiota-based drug development.

For biopharmaceutical leaders, the opportunity is expanding beyond gastrointestinal disease into immunology, oncology support, metabolic disorders, liver disease, neurology, and women's health. Success increasingly depends on validated biomarkers, reproducible manufacturing, donor or strain traceability, cold-chain and stability controls, and clinical endpoints that demonstrate durable patient benefit while meeting medicine-grade safety standards.

Transformative Shifts in the Microbiome Therapeutics Landscape

The microbiome therapeutics landscape is being reshaped by regulatory maturation, clinical selectivity, and a shift from broad fecal microbiota transfer toward defined microbial consortia and mechanism-led drug candidates. Developers are prioritizing indications with measurable dysbiosis, strong biological rationale, and clear unmet need rather than pursuing microbiome modulation as a generalized wellness claim.

Manufacturing is also transforming. Sponsors must prove identity, purity, potency, viability, and batch consistency while controlling contamination risk. This is pushing the sector toward GMP-grade anaerobic production, standardized donor screening, genomic characterization, validated potency assays, and scalable formulation technologies that can support capsules, rectal delivery, lyophilized products, and next-generation engineered strains.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is compounding the value of metagenomics, metabolomics, transcriptomics, proteomics, and clinical datasets by helping identify microbial signatures, predict patient response, and prioritize therapeutic consortia. In practice, AI is accelerating strain selection, functional pathway mapping, adverse event signal detection, trial enrichment, and biomarker discovery for patients most likely to benefit.

The cumulative impact is not automation alone; it is better decision quality across discovery, development, manufacturing, and commercialization. However, AI models require transparent validation, diverse datasets, explainability, privacy controls, and regulatory-grade documentation. Industry leaders that combine machine learning with prospective clinical evidence will be better positioned to move microbiome therapeutics from association-based claims to mechanism-supported interventions.

Key Regional Insights for Microbiome Therapeutics

North America remains the most clinically advanced region for microbiome therapeutics, supported by U.S. FDA approvals, mature clinical-trial infrastructure, academic microbiome centers, and a high burden of recurrent Clostridioides difficile infection linked to antibiotic exposure and healthcare-associated infections. The United States anchors trial activity and early commercialization, while Canada contributes through hospital networks, public health surveillance, and translational microbiome research.

Europe benefits from strong translational science, biobanking infrastructure, antimicrobial resistance programs, and coordinated European Union oversight for advanced therapies and medicinal products, although reimbursement pathways remain country-specific. Asia-Pacific is gaining momentum through China, Japan, South Korea, India, and Australia, where sequencing capacity, chronic disease burden, digital health adoption, and biologics manufacturing capabilities support clinical development. Latin America, led by Brazil and Mexico, is emerging through clinical collaborations, infectious disease expertise, and expanding specialty care access. The Middle East is advancing through genomics programs, precision medicine investment, and tertiary care expansion, while Africa remains at an earlier stage but has rising relevance due to infectious disease burden, antimicrobial resistance priorities, and the need for locally representative microbiome datasets.

Key Group Insights Across Global Market Alliances

The European Union is influential because its regulatory coordination, research funding, pharmacovigilance expectations, and data protection standards shape how microbiome therapeutics are evaluated, manufactured, and monitored. G7 markets provide the deepest mix of advanced healthcare infrastructure, reimbursement capacity, specialist clinicians, and clinical-trial ecosystems, making them critical for late-stage development and real-world evidence generation.

BRICS countries offer scale, biologic manufacturing capacity, growing genomics capabilities, and large patient populations for research expansion, especially in China, India, and Brazil. ASEAN markets are gaining relevance through regional healthcare modernization, medical tourism, infectious disease surveillance, and microbiome nutrition research. GCC countries are investing in national genomics, specialty care, biotechnology localization, and healthcare diversification, while NATO markets overlap heavily with high-income clinical research geographies that support resilient supply chains, regulatory cooperation, and secure biomanufacturing networks.

Key Country Insights Shaping Market Expansion

The United States leads commercialization because of FDA precedent, specialized clinical investors, advanced sequencing capacity, and a large infectious disease treatment base. Canada supports evidence generation through academic hospitals, microbiome research programs, and coordinated healthcare data systems, while Mexico and Brazil provide expanding clinical access, gastroenterology expertise, and regional relevance in Latin America. In Europe, the United Kingdom, Germany, France, Italy, and Spain combine advanced research hospitals, strong life-science clusters, and experience in regulated biologics, while Russia remains more constrained by geopolitical, funding, and regulatory complexity.

China is building scale in genomics, clinical research, and biomanufacturing; India offers a large patient base, cost-competitive clinical operations, and growing biotechnology capacity; Japan emphasizes quality systems, aging-related disease needs, and regulatory rigor; Australia contributes high-quality translational research and well-structured clinical trials; and South Korea combines biotechnology investment, hospital digitization, and advanced digital health infrastructure to support microbiome therapeutic development.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize indications with validated biology, feasible endpoints, and clear payer relevance. Recurrent Clostridioides difficile infection provides a proven starting point, but durable differentiation will come from patient stratification, mechanistic biomarkers, and evidence that microbiome modulation improves outcomes beyond standard care.

Executives should invest early in GMP manufacturing, strain characterization, donor screening where applicable, stability testing, potency assays, pharmacovigilance, and regulatory engagement. Partnerships with academic centers, sequencing platforms, AI specialists, contract manufacturers, and hospital networks can accelerate evidence generation, while disciplined pricing, reimbursement, and real-world evidence strategies will be essential for converting scientific promise into scalable adoption.

Research Methodology

This executive summary is based on triangulation of public regulatory records, peer-reviewed microbiome research, clinical-trial registries, health agency guidance, patent and policy signals, and macroeconomic healthcare indicators. Key reference areas include FDA actions on microbiota-based therapies, WHO and CDC antimicrobial resistance priorities, NIH-supported microbiome science, European regulatory guidance, and regional life-science policy developments.

The methodology emphasizes verified signals over speculative forecasts. Evidence was assessed across clinical validation, regulatory maturity, manufacturing readiness, geographic adoption, partnership activity, technology enablement, and healthcare system preparedness. Insights were synthesized to support strategic decision-making for biopharmaceutical, diagnostics, healthcare, and investment stakeholders.

Conclusion

Microbiome therapeutics are entering a decisive phase in which scientific novelty must be matched by clinical reproducibility, regulatory discipline, and manufacturing reliability. Approved microbiota-based therapies have validated the category, but the next wave will depend on defined mechanisms, patient selection, safety monitoring, and measurable long-term benefit.

Organizations that combine high-quality biological data, AI-enabled discovery, robust GMP production, validated biomarkers, and evidence-based market access strategies will be best positioned to lead. The future of microbiome therapeutics will favor developers that treat the microbiome not as a trend, but as a regulated therapeutic platform capable of addressing complex disease biology.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Microbiome Therapeutics Market, by Products

  • 7.1. Fecal Microbiota Transplantation
  • 7.2. Live-Biotherapeutics
  • 7.3. Microbiome Drugs
  • 7.4. Microbiome Ecosystem Therapies
  • 7.5. Probiotics & Prebiotics

8. Microbiome Therapeutics Market, by Therapeutic Area

  • 8.1. Autoimmune Diseases
  • 8.2. Cancer
  • 8.3. Gastrointestinal Disorders
  • 8.4. Infectious Diseases
  • 8.5. Metabolic Disorders
  • 8.6. Neurological Disorders

9. Microbiome Therapeutics Market, by Formulation

  • 9.1. Oral
  • 9.2. Topical

10. Microbiome Therapeutics Market, by Source

  • 10.1. Animal Microbiome
  • 10.2. Environmental Microbiome
  • 10.3. Human Microbiome

11. Microbiome Therapeutics Market, by End-use

  • 11.1. Academic & Research Institutions
  • 11.2. Hospitals & Clinics

12. Microbiome Therapeutics Market, by Distribution Channel

  • 12.1. Offline
    • 12.1.1. Hospital Pharmacies
    • 12.1.2. Retail Pharmacies
  • 12.2. Online Pharmacies

13. Microbiome Therapeutics Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Microbiome Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Microbiome Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Alveolus Bio, Inc. by ResBiotic
  • 17.2. AOBiome LLC
  • 17.3. Assembly Biosciences, Inc.
  • 17.4. Axial Therapeutics, Inc.
  • 17.5. BioGaia AB
  • 17.6. BiomeBank
  • 17.7. EnteroBiotix Ltd
  • 17.8. Enterome SA
  • 17.9. Ferring B.V.
  • 17.10. Intralytix, Inc.
  • 17.11. Kanvas Biosciences
  • 17.12. Locus Biosciences, Inc.
  • 17.13. MaaT Pharma SA
  • 17.14. Microba Life Sciences Limited
  • 17.15. Microbiotica Ltd.
  • 17.16. MRM Health NV
  • 17.17. NuBiyota
  • 17.18. Osel, Inc.
  • 17.19. Pendulum Therapeutics
  • 17.20. PharmaBiome AG
  • 17.21. Pylum Biosciences
  • 17.22. Seres Therapeutics, Inc.
  • 17.23. Servatus Limited
  • 17.24. Siolta Therapeutics
  • 17.25. Theriva Biologics, Inc.
  • 17.26. Vedanta Biosciences, Inc.
  • 17.27. Viome Life Sciences, Inc. by BlueDot LLC
  • 17.28. Xbiome Co. Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MICROBIOME THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL MICROBIOME THERAPEUTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL MICROBIOME THERAPEUTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL MICROBIOME THERAPEUTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL MICROBIOME THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL MICROBIOME THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL FECAL MICROBIOTA TRANSPLANTATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL FECAL MICROBIOTA TRANSPLANTATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL FECAL MICROBIOTA TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LIVE-BIOTHERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LIVE-BIOTHERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LIVE-BIOTHERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MICROBIOME DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MICROBIOME DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MICROBIOME DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MICROBIOME ECOSYSTEM THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MICROBIOME ECOSYSTEM THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MICROBIOME ECOSYSTEM THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PROBIOTICS & PREBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PROBIOTICS & PREBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PROBIOTICS & PREBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GASTROINTESTINAL DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GASTROINTESTINAL DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GASTROINTESTINAL DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANIMAL MICROBIOME MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANIMAL MICROBIOME MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANIMAL MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ENVIRONMENTAL MICROBIOME MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ENVIRONMENTAL MICROBIOME MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ENVIRONMENTAL MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ACADEMIC & RESEARCH INSTITUTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ACADEMIC & RESEARCH INSTITUTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ACADEMIC & RESEARCH INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA MICROBIOME THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA MICROBIOME THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE MICROBIOME THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST MICROBIOME THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN MICROBIOME THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 132. GCC MICROBIOME THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 133. GCC MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 134. GCC MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 135. GCC MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 136. GCC MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 137. GCC MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 138. GCC MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. GCC MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION MICROBIOME THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS MICROBIOME THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 156. G7 MICROBIOME THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 157. G7 MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 158. G7 MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 159. G7 MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 160. G7 MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 161. G7 MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 162. G7 MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. G7 MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 164. NATO MICROBIOME THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 165. NATO MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 166. NATO MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 167. NATO MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 168. NATO MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 169. NATO MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 170. NATO MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. NATO MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 181. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 183. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 184. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 185. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 186. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 187. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 189. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 191. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 192. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 193. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 194. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 195. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 197. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 198. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 199. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 200. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 201. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 202. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 203. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 213. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 214. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 215. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 216. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 217. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 218. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 219. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 220. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 221. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 222. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 223. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 224. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 225. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 226. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 227. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 229. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 231. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 232. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 233. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 234. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 235. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 236. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 237. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 238. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 239. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 240. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 241. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 242. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 243. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 244. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 245. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 247. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 248. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 249. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 250. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 251. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 252. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 261. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 262. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 263. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 264. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 265. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 266. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 267. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 268. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 269. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 270. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 271. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 272. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 273. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 274. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 275. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 276. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 277. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 279. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 280. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 281. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 282. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 283. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 284. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 285. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 286. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 287. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 288. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 289. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 290. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 291. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 292. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)